The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

The hepatitis B vaccine is the simplest yet most effective way to protect against hepatitis B infection Read on to know all ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Shares in clinical-stage biotechnology company INmune Bio ($INMB) collapsed over 60% today as it revealed mixed data from its ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

In the Phase 2 MINDFuL trial of XProTM in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat ...